Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
NCT ID: NCT05669287
Last Updated: 2023-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
125 participants
INTERVENTIONAL
2017-12-22
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main goal of the study is to create an AI-assisted method to classify patients with a vascular phenotype of pancreatic ductal adenocarcinoma (PDAC). The investigators expect that this phenotype can be used to predict overall survival and chemotherapy response.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Perfusion CT in Pancreatic Cancer
NCT01703650
CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer
NCT03012282
CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT03851237
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
NCT03032913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT Perfusion
All patients will receive a baseline CT Perfusion scan. A subgroup of patients with chemotherapy treatment will receive a follow-up CT Perfusion after 3 months.
CT Perfusion
CT Perfusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT Perfusion
CT Perfusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years and older
* written (signed and dated) informed consent
Exclusion Criteria
* Previous treatment for pancreatic cancer
* Concomitant malignancies. Subjects with prior malignancies must be disease-free for at least 5 years
* Insufficient command of the Dutch language to be able to understand the patient information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dutch Cancer Society
OTHER
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Hermans, MSc, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Radboud University Medical Center
Henkjan Huisman, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Radboud University Medical Center
Lodewijk Brosens
Role: PRINCIPAL_INVESTIGATOR
Radboud University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radboud University Medical Hospital
Nijmegen, Gelderland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12034
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
PERFUSION-PANC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.